维康药业
(300878)
| 流通市值：40.43亿 | | | 总市值：40.61亿 |
| 流通股本：1.44亿 | | | 总股本：1.45亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 151,317,754.3 | 114,569,884.83 | 69,775,938.28 | 351,198,567.67 |
| 营业收入 | 151,317,754.3 | 114,569,884.83 | 69,775,938.28 | 351,198,567.67 |
| 二、营业总成本 | 250,194,085.06 | 173,950,785.44 | 79,431,824.89 | 510,989,718.79 |
| 营业成本 | 128,101,243.85 | 89,624,143.06 | 33,910,536.12 | 217,105,289.06 |
| 税金及附加 | 4,446,881.58 | 1,868,155.04 | 1,505,227.41 | 11,711,547.79 |
| 销售费用 | 74,629,801.07 | 53,286,353.94 | 30,418,191.53 | 200,591,036.15 |
| 管理费用 | 30,723,857.75 | 20,193,443.14 | 9,612,289.15 | 61,138,368.81 |
| 研发费用 | 7,664,570.9 | 5,995,845.17 | 2,671,042 | 14,185,931.39 |
| 财务费用 | 4,627,729.91 | 2,982,845.09 | 1,314,538.68 | 6,257,545.59 |
| 其中:利息费用 | 5,659,028.07 | 3,782,750.26 | 1,935,369.66 | 9,335,228.93 |
| 其中:利息收入 | 1,108,946.45 | 848,072.42 | 487,268.13 | 3,147,465.84 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | - | - | - | 91,114,068 |
| 资产处置收益 | -1,002,485.43 | -493,861.61 | -168,841.23 | -467,667.6 |
| 资产减值损失(新) | -20,845,233.95 | -5,002,495.31 | 1,541,958.53 | -90,259,277.96 |
| 信用减值损失(新) | 8,828,033.75 | 6,894,944.48 | 4,867,447.87 | -3,183,567.33 |
| 其他收益 | 6,947,927.38 | 3,492,485.37 | 1,988,656.21 | 8,844,435.52 |
| 四、营业利润 | -104,948,089.01 | -54,489,827.68 | -1,426,665.23 | -153,743,160.49 |
| 加:营业外收入 | 754,553.47 | 255,442.25 | 267,133.28 | 2,988,544.68 |
| 减:营业外支出 | 7,823,272.09 | 2,047,875.44 | 1,057,649.5 | 7,521,368.49 |
| 五、利润总额 | -112,016,807.63 | -56,282,260.87 | -2,217,181.45 | -158,275,984.3 |
| 减:所得税费用 | 11,808,721.1 | 8,028,798.56 | 7,489,145.72 | -13,397,609.01 |
| 六、净利润 | -123,825,528.73 | -64,311,059.43 | -9,706,327.17 | -144,878,375.29 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -123,825,528.73 | -64,311,059.43 | -9,706,327.17 | -144,878,375.29 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -123,854,579.87 | -64,219,669.11 | -9,854,658.34 | -147,426,253.43 |
| 少数股东损益 | 29,051.14 | -91,390.32 | 148,331.17 | 2,547,878.14 |
| 扣除非经常损益后的净利润 | -122,188,938.22 | -64,826,322.34 | -10,544,817.79 | -238,936,373.43 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.86 | -0.44 | -0.07 | -1.03 |
| (二)稀释每股收益 | -0.86 | -0.44 | -0.07 | -1.03 |
| 九、综合收益总额 | -123,825,528.73 | -64,311,059.43 | -9,706,327.17 | -144,878,375.29 |
| 归属于母公司股东的综合收益总额 | -123,854,579.87 | -64,219,669.11 | -9,854,658.34 | -147,426,253.43 |
| 归属于少数股东的综合收益总额 | 29,051.14 | -91,390.32 | 148,331.17 | 2,547,878.14 |
| 公告日期 | 2025-10-30 | 2025-08-28 | 2025-04-29 | 2025-04-29 |
| 审计意见(境内) | | | | 保留意见 |